A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities - Interim Results of the "AZALE" Trial.
2010 | conference abstract. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities - Interim Results of the "AZALE" Trial.
Platzbecker, U.; Haase, D.; Braulke, F. ; Bug, G.; Goetze, K. S.; Kuendgen, A. & Roellig, C. et al. (2010)
Blood, 116(21) pp. 1630-1631. , Orlando, FL.
Washington: Amer Soc Hematology.
Documents & Media
Details
- Authors
- Platzbecker, Uwe; Haase, Detlef; Braulke, Friederike ; Bug, Gesine; Goetze, Katharina S.; Kuendgen, Andrea; Roellig, Christoph; Wermke, Martin; Naumann, Ralph; Bornhaeuser, Martin; Giagounidis, Aristoteles A. N.; Germing, Ulrich; Hofmann, Wolf-Karsten; Ehninger, Gerhard
- Issue Date
- 2010
- Status
- published
- Publisher
- Amer Soc Hematology
- Journal
- Blood
- Conference Place
- Orlando, FL
- ISSN
- 0006-4971
